查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2010060

糖尿病治疗市场：2026-2032年全球市场预测（依药物类别、给药途径、糖尿病类型、原产国及分销管道划分）

Diabetes Drugs Market by Drug Class, Route Of Administration, Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，糖尿病药物市场价值将达到 774 亿美元，到 2026 年将成长至 816.4 亿美元，到 2032 年将达到 1,172.5 亿美元，复合年增长率为 6.11%。

主要市场统计数据
基准年 2025 774亿美元
预计年份：2026年 816.4亿美元
预测年份 2032 1172.5亿美元
复合年增长率 (%) 6.11%

简要概述糖尿病治疗趋势的演变，将科学进步、获取趋势和商业性需求连结起来。

糖尿病药物市场正经历快速变革时期，这主要得益于药物类别、给药方式和商业策略的突破性进展。过去几年，临床进展重塑了治疗模式，而来自患者偏好和支付方的压力迫使製药公司不断创新，以提高药物的价值、便利性和患者依从性。因此，从生物製药公司经营团队到分销合作伙伴，相关人员都在重新评估优先事项，以平衡临床疗效、实际可及性和成本因素。

科学进步、数位医疗的融合以及供应链的韧性如何重塑糖尿病药物领域的临床实践和商业策略？

糖尿病领域正受到多种相互关联的因素的影响而发生变革，这些因素正在改变研发重点、临床实践和商业模式。肠促胰素生物学和胜肽类疗法的进步正在重新定义治疗流程，拓展治疗选择，并促使现有企业投资下一代分子和给药技术。同时，数位健康解决方案和远端监测使得数据驱动的用药依从性计画和真实世界数据在影响保险公司承保范围和指南采纳方面发挥着至关重要的作用。

本研究评估了 2025 年关税调整和贸易政策转变将如何重塑整个糖尿病价值链的采购、定价和供应链策略。

2025年贸易和关税体系的政策调整将为糖尿病生态系统中的製造商、经销商和付款方带来新的复杂性，促使他们重新评估采购、定价和库存策略。关税调整可能会增加成品和活性药物成分的采购成本，迫使采购团队重新评估供应商选择，实现供应来源多元化，并增加对区域製造合作伙伴的依赖，以降低风险。因此，这些决策会影响与支付方和采购实体之间的合约动态，因为企业需要在确保获利能力和供应连续性的同时，努力保持价格竞争力。

透过利用多方面的细分洞察，将药物类别、给药途径、患者类型、来源和分销管道结合起来，我们明确了临床和商业性重点。

透过识别临床需求、商业性机会和营运要求之间的交集，细分有助于明确策略规划。药物类别包括Amylin类似物、GLP-1受体促效剂、胰岛素和口服降血糖药物（OADs），胰岛素可细分为长效和短效两类。此框架突显了不同的研发路径。胜肽类肠促胰岛素疗法强调药物的持久性和代谢获益，而胰岛素领域由于其药物动力学特性，需要独特的给药方法和低温运输管理。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势，以及它们各自的准入途径，正在塑造监管策略和供应选择。

随着糖尿病治疗在不同医疗生态系统中不断发展，区域趋势持续影响竞争策略、监管策略和製造地。在美洲，市场动态强调与支付方的谈判、整合式医疗路径以及在基层医疗和专科医疗机构中采用创新技术。报销方式和药品福利管理机构的角色影响处方药清单和患者准入计划，从而创造出优先考虑长期疗效和成本效益的环境。

领先的糖尿病相关企业如何透过其深厚的科学研究研发管线、策略联盟和生产整合来重塑其竞争定位和价值提案。

主要企业之间的竞争格局反映了强大的科学研究管线、策略联盟和生产管理能力的整合。老牌製药公司持续投资于产品生命週期延长、给药方式创新和以疗效主导的市场定位，以巩固其高端市场地位。同时，生技公司和专科药物研发企业则专注于突破性的作用机制和差异化的获益风险比，以吸引合作伙伴并达成授权协议。

采取切实可行的跨部门策略措施，协调研发重点、供应多元化、支付方合作和数位整合，以确保竞争优势。

产业领导企业必须推动一系列协调一致的倡议，将技术和政策变革转化为永续的竞争优势。首先，企业应使其研发重点与尚未满足的需求和支付方的证据要求保持一致，投资于能够证明长期、可持续疗效和成本节约的终点指标。同时，产品组合经理需要评估服务途径创新以及与医疗设备的协同效应，这些创新和协同效应能够显着提高患者的用药依从性，并在竞争激烈的治疗领域中实现产品差异化。

为了确保实用见解，我们采用透明的混合方法研究途径，将与专家的初步访谈、二手文献综述和基于情境的检验相结合。

本研究途径结合了结构化的原始研究和严谨的二手研究，并采用方法论三角验证调查方法，确保了研究结果的稳健性和实用性。原始资料来源包括对临床专业人员、供应链负责人、销售主管和支付方的访谈，旨在了解他们对治疗方法采纳、报销趋势和营运重点的前瞻性观点。这些定性见解与监管文件、同行评审的临床文献和公司资讯披露进行交叉比对，以检验技术声明和研发轨迹。

透过对策略挑战的综合分析，确保长期定位，这些策略挑战包括临床差异化、营运韧性和与支付方的价值一致性。

总而言之，糖尿病治疗领域正处于一个转折点，科学创新、以患者为中心的医疗服务模式和政策趋势在此交汇，重新定义了竞争和运作的重点。那些能够整合深度临床差异化、稳健的供应策略以及与支付方相契合的价值提案的相关人员，将最有可能获得永续优势。在报销额度有限的环境下，对真实世界证据和患者体验的双重关注，对于决定哪些治疗方法能够获得广泛应用和优先推广至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 糖尿病治疗市场：依药物类别划分

  • Amylin类似物
  • GLP-1受体促效剂
  • 胰岛素
    • 长效型
    • 快速起效
  • 口服降血糖药（OADs）

第九章：糖尿病治疗市场：依给药途径划分

  • 吸入
  • 注射药物
  • 口服

第十章 糖尿病治疗市场：依糖尿病类型划分

  • 1型糖尿病
  • 2型糖尿病

第十一章 糖尿病治疗市场：依药物来源划分

  • 品牌药品
  • 学名药

第十二章 糖尿病药物市场：依分销管道划分

  • 家庭医疗保健
  • 医院药房
  • 网路药房
  • 零售药房

第十三章 糖尿病药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 糖尿病药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 糖尿病药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国糖尿病治疗市场

第十七章：中国糖尿病治疗药物市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson and Johnson
  • Merck and Co Inc
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-434CCDA051C3

The Diabetes Drugs Market was valued at USD 77.40 billion in 2025 and is projected to grow to USD 81.64 billion in 2026, with a CAGR of 6.11%, reaching USD 117.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 77.40 billion
Estimated Year [2026] USD 81.64 billion
Forecast Year [2032] USD 117.25 billion
CAGR (%) 6.11%

A succinct orientation to the evolving diabetes therapeutics landscape that connects scientific advances, access dynamics, and commercial imperatives

The diabetes therapeutics landscape is experiencing a period of concentrated evolution driven by breakthroughs in drug classes, delivery modalities, and commercial strategies. Over the past several years clinical advances have reshaped treatment paradigms, while patient preferences and payer pressures have simultaneously driven manufacturers to innovate on value, convenience, and adherence. As a result, stakeholders from biopharma executives to distribution partners are recalibrating priorities to reconcile clinical effectiveness with practical access and cost considerations.

This introduction situates readers within the broader context of these converging forces. It emphasizes the interplay between therapeutic innovation and structural shifts in supply chains and reimbursement. The narrative that follows explores transformative shifts across science and commercialization, assesses policy impacts such as tariff changes with cross-border implications, and translates segmentation and regional dynamics into practical insights for leaders. The goal is to provide an integrated, evidence-based foundation for strategy development that aligns scientific opportunity with operational and commercial realities.

How converging scientific advances, digital health integration, and supply chain resilience are reshaping clinical practice and commercial strategies across diabetes therapeutics

The diabetes landscape is being transformed by several interdependent forces that are altering development priorities, clinical practice, and commercial models. Advances in incretin biology and peptide therapeutics have redefined treatment algorithms and expanded the therapeutic toolkit, prompting incumbents to invest in next-generation molecules and delivery technologies. Concurrently, digital health solutions and remote monitoring have elevated the role of data-driven adherence programs and real-world evidence in shaping payer coverage and guideline adoption.

Supply chain resilience and regional manufacturing investments are increasingly strategic priorities, with companies re-evaluating sourcing footprints to reduce exposure to disruptions. Strategic collaborations and platform licensing deals are accelerating, enabling smaller innovators to scale without extensive capital outlay while allowing larger players to broaden their pipelines. These shifts heighten competition but also create windows for differentiation through patient-centric delivery formats, integrated care models, and differentiated value propositions focused on long-term outcomes rather than episodic interventions.

Assessing how recent tariff adjustments and trade policy shifts in 2025 have reconfigured sourcing, pricing, and supply chain strategies across the diabetes value chain

Policy shifts in trade and tariff regimes in 2025 have introduced new complexities for manufacturers, distributors, and payers in the diabetes ecosystem, prompting reappraisals of sourcing, pricing, and inventory strategies. Tariff adjustments can elevate landed costs for finished formulations and active pharmaceutical ingredients, prompting procurement teams to revisit supplier selection, diversify supply bases, and increase reliance on regional manufacturing partners to mitigate exposure. In turn, these decisions influence contracting dynamics with payers and procurement bodies as firms aim to preserve price competitiveness while protecting margin and supply continuity.

Beyond direct cost effects, tariff-driven supply chain responses can accelerate local invest-ment in manufacturing capacity, influencing long-term competitive positioning. Regulatory compliance, customs clearance timelines, and documentation requirements have become focal areas for supply chain teams, as delays can propagate downstream to hospital pharmacies and outpatient access points. Companies that proactively model tariff scenarios and implement flexible sourcing, multi-origin procurement strategies, and near-shore manufacturing options will be better positioned to absorb policy shocks and sustain market access across geographies.

Multidimensional segmentation insights that align drug class, administration route, patient type, origin, and distribution channel to prioritize clinical and commercial priorities

Segmentation drives clarity in strategic planning by revealing where clinical need, commercial opportunity, and operational requirements intersect. Based on Drug Class, the landscape includes Amylin Analogs, GLP-1 Receptor Agonists, Insulin, and Oral Antidiabetic Drugs (OADs), with Insulin further delineated into Long Acting and Short-Acting categories. This framing highlights divergent development pathways: peptide-based incretin therapies emphasize durability and metabolic benefits, whereas insulin segments require differentiated delivery and cold-chain considerations tied to formulation kinetics.

Based on Route Of Administration, therapies span Inhalation, Injectable, and Oral formats, each carrying distinct adherence profiles, device development imperatives, and regulatory pathways. Delivery route choices drive patient experience and real-world persistence, and therefore directly influence positioning and reimbursement conversations. Based on Diabetes Type, the pipeline and product mix serve both Type 1 Diabetes and Type 2 Diabetes populations; clinical needs and care settings vary substantially between these cohorts, necessitating tailored engagement strategies for providers and payers.

Based on Drug Origin, offerings are categorized as Branded Drugs and Generic Drugs, a distinction that affects lifecycle management, price sensitivity, and competitive dynamics. Branded innovators focus on differentiation through outcomes and ancillary services, while generic entrants concentrate on cost leadership and supply continuity. Based on Distribution Channel, products reach patients through Home Healthcare, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy routes, and each channel imposes unique logistics, reimbursement, and patient education requirements. When these segmentation lenses are combined, they create a multi-dimensional view of opportunity and risk that supports prioritization of assets, channel strategies, and investment decisions.

Regional dynamics and differentiated access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy and supply choices

Regional dynamics continue to shape competitive agendas, regulatory strategies, and manufacturing footprints as diabetes care evolves across diverse healthcare ecosystems. In the Americas, market dynamics emphasize payer negotiations, integrated care pathways, and innovation adoption in both primary care and specialist settings. Reimbursement approaches and the role of pharmacy benefit managers impact formulary positioning and patient access programs, creating an environment where evidence of long-term outcomes and cost-effectiveness can unlock preferential placement.

The Europe, Middle East & Africa region offers heterogenous regulatory landscapes and procurement models, with some countries emphasizing centralized tendering and others relying on decentralized reimbursement decisions. This diversity requires tailored regulatory strategies, localized evidence packages, and flexible pricing models to navigate public procurement, hospital purchasing, and national health system priorities. Similarly, Asia-Pacific presents a mix of high-growth demand centers, price-sensitive markets, and rapidly expanding domestic manufacturing capability. Local production and regulatory endorsement can significantly accelerate market entry, while cross-border trade policies and regional partnerships influence supply chain resilience and competitive dynamics. Across all regions, the interplay between local regulation, payer structure, and manufacturing location informs go-to-market sequencing and long-term investment choices.

How scientific pipeline depth, strategic alliances, and manufacturing integration are reshaping competitive positions and value propositions among leading diabetes players

Competitive dynamics among leading companies reflect a blend of deep scientific pipelines, strategic alliances, and manufacturing control. Established pharmaceutical firms continue to invest in lifecycle extensions, delivery innovations, and outcome-driven positioning to protect premium segments. Meanwhile, biotech players and specialty developers focus on breakthrough mechanisms and differentiated benefit-risk profiles that attract partnership interest and licensing arrangements.

Across the sector, companies are prioritizing vertical integration for critical components such as peptide synthesis and cold-chain logistics to reduce exposure to supply disruptions. Strategic alliances frequently couple small-molecule or biologic innovators with larger commercialization partners to accelerate scale and market access. Additionally, the rise of biosimilars and generics in key insulin segments has intensified competition on price and supply security, prompting incumbent companies to emphasize service-based differentiation, patient support programs, and bundled care solutions to sustain brand value.

Practical, cross-functional strategic moves that align R&D priorities, supply diversification, payer engagement, and digital integration to secure competitive advantage

Industry leaders must pursue a coordinated set of actions to translate technological and policy shifts into sustainable advantage. First, companies should align R&D priorities with unmet clinical needs and payer evidence requirements, investing in endpoints that demonstrate durable outcomes and cost offsets over time. In parallel, portfolio managers should evaluate route-of-administration innovations and device synergies that can meaningfully enhance adherence and differentiate offerings in crowded therapeutic classes.

Operationally, firms need to diversify sourcing and accelerate regional manufacturing capabilities to hedge against tariff and trade volatility while shortening lead times for critical ingredients. Commercial teams should deepen engagement with payers and health systems to co-design value agreements and outcomes-based contracts that reflect real-world performance. Moreover, cross-functional investments in digital adherence platforms and remote monitoring should be scaled to support clinical claims with real-world data and strengthen patient retention. Finally, organizations should pursue selective partnerships and licensing arrangements to access complementary capabilities rapidly, balancing internal development with external innovation to maintain agility.

A transparent mixed-methods research approach integrating expert primary interviews, secondary literature review, and scenario-based triangulation to ensure actionable insights

The research approach combines structured primary research with rigorous secondary analysis and methodological triangulation to ensure robustness and practical relevance. Primary inputs included interviews with clinical experts, supply chain leaders, commercial executives, and payers to capture forward-looking perspectives on therapeutic adoption, reimbursement dynamics, and operational priorities. These qualitative insights were triangulated with regulatory filings, peer-reviewed clinical literature, and company disclosures to validate technical claims and development trajectories.

Data synthesis employed scenario analysis to test supply chain and policy sensitivities, while thematic coding distilled recurring strategic imperatives across stakeholders. Quality controls included cross-validation of interview findings with public filings and expert peer review to mitigate bias. Limitations include variability in regional reporting standards and the evolving nature of policy environments; the methodology addresses these by emphasizing scenario-based guidance rather than prescriptive numeric forecasts and by documenting assumptions that underpin strategic implications.

Concluding synthesis of strategic imperatives that combine clinical differentiation, operational resilience, and payer-aligned value to secure long-term positioning

In summary, the diabetes therapeutics domain is at an inflection point where scientific innovation, patient-centered delivery, and policy dynamics intersect to redefine competitive and operational priorities. Stakeholders who integrate deep clinical differentiation with resilient supply strategies and payer-aligned value propositions will be best positioned to capture sustainable advantages. The dual focus on real-world evidence and patient experience will increasingly determine which therapies achieve broad adoption and preferred positioning within constrained reimbursement environments.

Leaders should view the current environment as an opportunity to accelerate investments in differentiated delivery formats, regional manufacturing, and outcome-focused engagements. Those that act decisively to align clinical development with commercial access imperatives and operational resilience will create defensible positioning in an increasingly complex global landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Drugs Market, by Drug Class

  • 8.1. Amylin Analogs
  • 8.2. GLP-1 Receptor Agonists
  • 8.3. Insulin
    • 8.3.1. Long Acting
    • 8.3.2. Short-Acting
  • 8.4. Oral Antidiabetic Drugs (OADs)

9. Diabetes Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Diabetes Drugs Market, by Diabetes Type

  • 10.1. Type 1 Diabetes
  • 10.2. Type 2 Diabetes

11. Diabetes Drugs Market, by Drug Origin

  • 11.1. Branded Drugs
  • 11.2. Generic Drugs

12. Diabetes Drugs Market, by Distribution Channel

  • 12.1. Home Healthcare
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Diabetes Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diabetes Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diabetes Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Diabetes Drugs Market

17. China Diabetes Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Astellas Pharma Inc
  • 18.6. AstraZeneca plc
  • 18.7. Bayer AG
  • 18.8. Biocon Limited
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Cipla Limited
  • 18.12. Daiichi Sankyo Company Limited
  • 18.13. Eli Lilly and Company
  • 18.14. GlaxoSmithKline plc
  • 18.15. Johnson and Johnson
  • 18.16. Merck and Co Inc
  • 18.17. Novartis AG
  • 18.18. Novo Nordisk A S
  • 18.19. Pfizer Inc
  • 18.20. Roche Holding AG
  • 18.21. Sanofi S A
  • 18.22. Sun Pharmaceutical Industries Ltd
  • 18.23. Takeda Pharmaceutical Company Limited
  • 18.24. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. GCC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 130. GCC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. G7 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 148. G7 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. NATO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 155. NATO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. NATO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)